Godec Jernej, Cowley Glenn S, Barnitz R Anthony, Alkan Ozan, Root David E, Sharpe Arlene H, Haining W Nicholas
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; Department of Microbiology and Immunobiology, Harvard Medical School, and Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115;
Broad Institute of MIT and Harvard, Cambridge, MA 02142;
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):512-7. doi: 10.1073/pnas.1413291112. Epub 2014 Dec 29.
The differentiation of effector CD8(+) T cells is critical for the development of protective responses to pathogens and for effective vaccines. In the first few hours after activation, naive CD8(+) T cells initiate a transcriptional program that leads to the formation of effector and memory T cells, but the regulation of this process is poorly understood. Investigating the role of specific transcription factors (TFs) in determining CD8(+) effector T-cell fate by gene knockdown with RNAi is challenging because naive T cells are refractory to transduction with viral vectors without extensive ex vivo stimulation, which obscures the earliest events in effector differentiation. To overcome this obstacle, we developed a novel strategy to test the function of genes in naive CD8(+) T cells in vivo by creating bone marrow chimera from hematopoietic progenitors transduced with an inducible shRNA construct. Following hematopoietic reconstitution, this approach allowed inducible in vivo gene knockdown in any cell type that developed from this transduced progenitor pool. We demonstrated that lentivirus-transduced progenitor cells could reconstitute normal hematopoiesis and develop into naive CD8(+) T cells that were indistinguishable from wild-type naive T cells. This experimental system enabled induction of efficient gene knockdown in vivo without subsequent manipulation. We applied this strategy to show that the TF BATF is essential for initial commitment of naive CD8(+) T cells to effector development but becomes dispensable by 72h. This approach makes possible the study of gene function in vivo in unperturbed cells of hematopoietic origin that are refractory to viral transduction.
效应性CD8(+) T细胞的分化对于机体对病原体产生保护性反应以及有效疫苗的研发至关重要。在激活后的最初几个小时内,初始CD8(+) T细胞启动一个转录程序,该程序导致效应性和记忆性T细胞的形成,但这一过程的调控机制尚不清楚。通过RNA干扰进行基因敲低来研究特定转录因子(TFs)在决定CD8(+)效应性T细胞命运中的作用具有挑战性,因为未经大量体外刺激的初始T细胞对病毒载体转导具有抗性,这掩盖了效应性分化中最早发生的事件。为了克服这一障碍,我们开发了一种新策略,通过用可诱导的短发夹RNA构建体转导造血祖细胞来创建骨髓嵌合体,从而在体内测试初始CD8(+) T细胞中基因的功能。造血重建后,这种方法允许在源自该转导祖细胞池的任何细胞类型中进行体内可诱导的基因敲低。我们证明,慢病毒转导的祖细胞可以重建正常造血,并发育成与野生型初始T细胞无法区分的初始CD8(+) T细胞。这个实验系统能够在体内诱导高效的基因敲低,而无需后续操作。我们应用这一策略表明,转录因子BATF对于初始CD8(+) T细胞向效应性发育的初始定向至关重要,但在72小时后变得不再必要。这种方法使得在对病毒转导具有抗性的造血来源的未受干扰细胞中研究体内基因功能成为可能。